Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Bishop

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Ocular Immunology and Inflammation|April 24, 2019
Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic MalignanciesCarl W Noble, Sapna S Gangaputra, Ian A Thompson, et al.
Ophthalmology|June 25, 2021
ReplyM Teresa Magone, Iris R Hartley, Edmond FitzGibbon, et al.
Ophthalmology|September 5, 2020
Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase InhibitorM Teresa Magone, Iris R Hartley, Edmond Fitzgibbon, et al.
The Journal of Allergy and Clinical Immunology|August 22, 2015
Endemic mycoses in patients with STAT3-mutated hyper-IgE (Job) syndromeCamila D Odio, Ki Lee Milligan, Katherine McGowan, et al.
Ophthalmology|October 20, 2018
DICER1 Syndrome: Characterization of the Ocular Phenotype in a Family-Based Cohort StudyLaryssa A Huryn, Amy Turriff, Laura A Harney, et al.
Investigational New Drugs|August 16, 2017
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profileGiovanna Speranza, Larry Anderson, Alice P Chen, et al.
The American Journal of Cardiology|June 7, 2017
Hospital Inpatient Costs for Single Ventricle Patients Surviving the Fontan ProcedureLi Huang, Chris Schilling, Kim M Dalziel, et al.
Investigational New Drugs|June 18, 2015
Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumorsKhanh Do, Giovanna Speranza, Lun-Ching Chang, et al.
Annals of the Rheumatic Diseases|June 8, 2014
A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory diseaseCailin H Sibley, Andrea Chioato, Sandra Felix, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2019
Prospective International Study of Incidence and Predictors of Immune Reconstitution Inflammatory Syndrome and Death in People Living With Human Immunodeficiency Virus and Severe LymphopeniaIrini Sereti, Virginia Sheikh, Douglas Shaffer, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Ocular Immunology and Inflammation|April 24, 2019
Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic MalignanciesCarl W Noble, Sapna S Gangaputra, Ian A Thompson, et al.
Ophthalmology|June 25, 2021
ReplyM Teresa Magone, Iris R Hartley, Edmond FitzGibbon, et al.
Ophthalmology|September 5, 2020
Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase InhibitorM Teresa Magone, Iris R Hartley, Edmond Fitzgibbon, et al.
The Journal of Allergy and Clinical Immunology|August 22, 2015
Endemic mycoses in patients with STAT3-mutated hyper-IgE (Job) syndromeCamila D Odio, Ki Lee Milligan, Katherine McGowan, et al.
Ophthalmology|October 20, 2018
DICER1 Syndrome: Characterization of the Ocular Phenotype in a Family-Based Cohort StudyLaryssa A Huryn, Amy Turriff, Laura A Harney, et al.
Investigational New Drugs|August 16, 2017
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profileGiovanna Speranza, Larry Anderson, Alice P Chen, et al.
The American Journal of Cardiology|June 7, 2017
Hospital Inpatient Costs for Single Ventricle Patients Surviving the Fontan ProcedureLi Huang, Chris Schilling, Kim M Dalziel, et al.
Investigational New Drugs|June 18, 2015
Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumorsKhanh Do, Giovanna Speranza, Lun-Ching Chang, et al.
Annals of the Rheumatic Diseases|June 8, 2014
A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory diseaseCailin H Sibley, Andrea Chioato, Sandra Felix, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2019
Prospective International Study of Incidence and Predictors of Immune Reconstitution Inflammatory Syndrome and Death in People Living With Human Immunodeficiency Virus and Severe LymphopeniaIrini Sereti, Virginia Sheikh, Douglas Shaffer, et al.
Pageof 4